{
    "clinical_study": {
        "@rank": "163313", 
        "acronym": "ACTorNOT", 
        "arm_group": [
            {
                "arm_group_label": "Expectant Management", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will have their PPUL expectantly managed using serum hCG monitoring."
            }, 
            {
                "arm_group_label": "Uterine evacuation with MTX for some", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required."
            }, 
            {
                "arm_group_label": "Empiric treatment with MTX for all", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized controlled trial to compare three currently available management\n      strategies for women with a persisting pregnancy of unknown location (PPUL), which makes\n      them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a\n      confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed\n      by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic\n      pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will\n      be 1:1:1 into these three arms. After randomization, they will be followed and treated\n      clinically as is indicated by the progression of their condition. Primary outcome measures:\n      uneventful decline of hCG to 5 IU/mL."
        }, 
        "brief_title": "Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Persistent Pregnancy of Unknown Location", 
            "Ectopic Pregnancy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pregnancy, Ectopic", 
                "Cardiac Complexes, Premature"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female with a persisting pregnancy of unknown location:\n\n          -  A pregnancy of unknown location is defined as a pregnancy in a woman with a positive\n             pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on\n             ultrasound imaging.  A definitive sign of gestation includes ultrasound visualization\n             of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in\n             the adnexa.  Ultrasound must be performed within 7 days prior to randomization.\n\n          -  Persistence of hCG is defined as at least 2 serial hCG values (over 4-14 days),\n             showing < 50% rise, or < 50% fall between the first and last value.\n\n          -  Patient is hemodynamically stable, hemoglobin >10 mg/dL\n\n          -  Greater than or 18 years of age\n\n        Exclusion Criteria:\n\n          -  Hemodynamically unstable in need of acute treatment\n\n          -  Most recent hCG > 5000 mIU/mL\n\n          -  Patient obtaining care in relation to a recently completed pregnancy   (delivery,\n             spontaneous or elective abortion)\n\n          -  Diagnosis of gestational trophoblastic disease\n\n          -  Subject unwilling or unable to comply with study procedures\n\n          -  Presence of clinical contraindications for treatment with MTX\n\n          -  Prior medical or surgical management of this gestation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "276", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152696", 
            "org_study_id": "ACTorNOT"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Uterine evacuation with MTX for some", 
                    "Empiric treatment with MTX for all"
                ], 
                "description": "Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Uterine evacuation with MTX for some", 
                "description": "Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.", 
                "intervention_name": "Uterine Evacuation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Expectant Management", 
                "description": "Pregnancy will be expectantly managed using serum hcg monitoring", 
                "intervention_name": "Expectant Management", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "coedwards@gru.edu", 
                    "last_name": "Connie Edwards", 
                    "phone": "706-721-0193"
                }, 
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Georgia Regents University"
                }, 
                "investigator": {
                    "last_name": "Michael Diamond, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jinny_eun@med.unc.edu", 
                    "last_name": "Jinny Eun", 
                    "phone": "919-966-5283"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina"
                }, 
                "investigator": {
                    "last_name": "Anne Steiner, MD, MPH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Michelle-Rodriguez@ouhsc.edu", 
                    "last_name": "Michelle Rodriguez", 
                    "phone": "405-271-1616"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma"
                }, 
                "investigator": {
                    "last_name": "Karl Hansen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jober@hmc.psu.edu", 
                    "last_name": "Jamie Ober", 
                    "phone": "717-531-6272"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Pennsylvania State University"
                }, 
                "investigator": {
                    "last_name": "Richard Legro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "RMarunich@obgyn.upenn.edu", 
                    "last_name": "Jean Marunich", 
                    "phone": "215-662-2935"
                }, 
                "contact_backup": {
                    "email": "Ashley.Singer@uphs.upenn.edu", 
                    "last_name": "Ashley Singer"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": [
                    {
                        "last_name": "Kurt Barnhart, MD, MSCE", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Christos Coutifaris, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure in each of each 3 treatment arm is the uneventful clinical resolution of a PPUL without change from the initial management strategy.", 
            "measure": "Uneventful clinical resolution of a Pregnancy of Unknown Location without change from the initial management strategy", 
            "safety_issue": "No", 
            "time_frame": "6 weeks from randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152696"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Heping Zhang", 
            "investigator_title": "Primary Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Georgia Regents University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Penn State University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, San Francisco", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of North Carolina", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Oklahoma", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Pennsylvania", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}